Publications by authors named "Kaiqin Sheng"
Article Synopsis
- Gastric cancer (GC) has low survival rates and limited treatment options, often associated with mutations in the ARID1A gene, prompting the exploration of novel therapies.
- Researchers screened 551 kinase inhibitors and found AZD5363 (an AKT inhibitor) to be the most effective in targeting ARID1A-deficient cancer cells by inducing synthetic lethality.
- The mechanism involves AZD5363 causing pyroptotic cell death through the Caspase-3/GSDME pathway while also revealing that ARID1A normally represses AKT expression, explaining its increased activity in deficient cells.
Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) has been identified as a crucial immune suppressor in human cancers, comparable to programmed cell death 1 ligand (PD-L1). However, the regulatory mechanisms underlying its transcriptional upregulation in human cancers remain largely unknown. Here, we show that the transcription factors ETS-1 and ETS-2 bound to the Siglec-15 promoter to enhance transcription and expression of Siglec-15 in hepatocellular carcinoma (HCC) cells and that transforming growth factor β-1 (TGF-β1) upregulated the expression of ETS-1 and ETS-2 and facilitated the binding of ETS-1 and ETS-2 to the Siglec-15 promoter.
View Article and Find Full Text PDFHBx is a short-lived protein whose rapid turnover is mainly regulated by ubiquitin-dependent proteasomal degradation pathways. Our prior work identified BAF155 to be one of the HBx binding partners. Since BAF155 has been shown to stabilize other members of the SWI/SNF chromatin remodelling complex by attenuating their proteasomal degradation, we proposed that BAF155 might also contribute to stabilizing HBx protein in a proteasome-dependent manner.
View Article and Find Full Text PDF